MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to acquire Mirus Bio for approximately US$ 600 million (around € 550 million), following regulatory clearances and the fulfillment of other customary closing conditions. The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. The Life Science business of Merck KGaA, Darmstadt, Germany acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.
Read the full article: MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering //
Source: https://www.businesswire.com/news/home/20240801851971/en/MilliporeSigma-Announces-Closing-of-Mirus-Bio-Acquisition-Bolstering-Viral-Vector-Bioprocessing-Offering